التفاصيل البيبلوغرافية
| العنوان: |
Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. |
| المؤلفون: |
Bachelez, H., Griffiths, C. E. M., Papp, K. A., Hall, S., Merola, J. F., Feldman, S. R., Khraishi, M., Tan, H., Fallon, L., Cappelleri, J. C., Bushmakin, A. G., Young, P. |
| المصدر: |
Journal of the European Academy of Dermatology & Venereology; Jul2024, Vol. 38 Issue 7, pe557-e561, 5p |
| مصطلحات موضوعية: |
PSORIATIC arthritis, PATIENT reported outcome measures, PATIENT safety, HYPERCOAGULATION disorders |
| مستخلص: |
This document provides a summary of a study on the use of tofacitinib in patients with psoriasis and a history of psoriatic arthritis (PsA). The study found that tofacitinib, at both 5mg and 10mg doses, resulted in significant improvements in skin disease, itch, joint pain, morning stiffness, and depressive symptoms compared to a placebo. The safety profile of tofacitinib was consistent with previous reports. The study suggests that these findings can inform clinical practice and the scientific community. The limitations of the study include the reliance on patient reports for PsA history. The study was sponsored by Pfizer, and the authors disclosed various conflicts of interest. [Extracted from the article] |
|
Copyright of Journal of the European Academy of Dermatology & Venereology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder